Physician profile
Alla Iospa
NPI 1710058896
$3,774.87
in general payments reported to CMS, 2019-2025
17 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $46.39 · 2022: $180 · 2023: $476 · 2024: $699 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018 · Education: $99.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.68 |
| Education | $99.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $500.49 | 2019-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $462.89 | 2023-2025 | |
| Alkermes, INC. | $456.81 | 2024-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $432.27 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.76 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $299.81 | 2020-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $267.96 | 2023-2025 | Uzedy |
| Lundbeck LLC | $202.47 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $197.68 | 2019-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $175.52 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $128.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $85.25 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $71.77 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $42.76 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.95 | 2025 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.06 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Iospa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.